Catalyst Brief

← Calendar

Readoutin 14d

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264

Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.

Date
Dec 2026
Type
Readout
Indication
Non-Small Cell Lung Cancer

Source ↗Add to calendar

Date history

May 1, 2027 → Dec 1, 2026Nov 17, 2026
Dec 1, 2026 → May 1, 2027Nov 17, 2026
May 1, 2027 → Dec 1, 2026Nov 17, 2026

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  1. May2027
  2. Nov2026